Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Publikation

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Wissenschaftlicher Artikel/Review - 21.02.2015

Samaras Panagiotis, Zander Thilo, Taverna Christian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Hess Urs, Heim Dominik, Duchosal Michel A, Betticher Daniel C, Bargetzi Mario, Renner Christoph

Zitation

Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2015; 145:w14100.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Swiss Med Wkly 2015; 145

Veröffentlichungsdatum

21.02.2015

eISSN (Online)

1424-3997

Seiten

w14100

Kurzbeschreibung/Zielsetzung

The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss expert panel to re-evaluate the current status and formulate updated clinical recommendations for the diagnosis and treatment of plasma cell myeloma. These recommendations should help clinicians in their decision making to achieve the best outcome based on currently available data.